vs
Alector, Inc.（ALEC）与艾伯维（ARGX）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是Alector, Inc.的396.6倍（$2.5B vs $6.2M）。艾伯维净利率更高（35.5% vs -597.5%，领先633.0%）。艾伯维同比增速更快（83.2% vs -88.5%）
Alector是一家临床阶段生物制药企业，专注于神经退行性疾病的免疫疗法研发，管线覆盖阿尔茨海默病、额颞叶痴呆、帕金森病等未被满足的医疗需求，主要在美国运营，与全球药企合作推进候选药物的临床试验。
艾伯维是总部位于美国伊利诺伊州北芝加哥的制药企业，研发生产的药物覆盖多种疾病治疗领域，可满足多元临床需求，致力于为全球不同病症的患者提供可靠的治疗方案选择。
ALEC vs ARGX — 直观对比
营收规模更大
ARGX
是对方的396.6倍
$6.2M
营收增速更快
ARGX
高出171.7%
-88.5%
净利率更高
ARGX
高出633.0%
-597.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $6.2M | $2.5B |
| 净利润 | $-37.3M | $877.2M |
| 毛利率 | — | 89.5% |
| 营业利润率 | -634.4% | 28.9% |
| 净利率 | -597.5% | 35.5% |
| 营收同比 | -88.5% | 83.2% |
| 净利润同比 | -1696.9% | 1.3% |
| 每股收益（稀释后） | $-0.34 | $13.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALECARGX
| Q4 25 | $6.2M | $2.5B | ||
| Q3 25 | $3.3M | — | ||
| Q2 25 | $7.9M | $1.8B | ||
| Q1 25 | $3.7M | — | ||
| Q4 24 | $54.2M | $1.4B | ||
| Q3 24 | $15.3M | — | ||
| Q2 24 | $15.1M | $901.9M | ||
| Q1 24 | $15.9M | — |
净利润ALECARGX
| Q4 25 | $-37.3M | $877.2M | ||
| Q3 25 | $-34.7M | — | ||
| Q2 25 | $-30.5M | $414.8M | ||
| Q1 25 | $-40.5M | — | ||
| Q4 24 | $-2.1M | $865.6M | ||
| Q3 24 | $-42.2M | — | ||
| Q2 24 | $-38.7M | $-32.5M | ||
| Q1 24 | $-36.1M | — |
毛利率ALECARGX
| Q4 25 | — | 89.5% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 89.2% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 90.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 89.4% | ||
| Q1 24 | — | — |
营业利润率ALECARGX
| Q4 25 | -634.4% | 28.9% | ||
| Q3 25 | -1153.6% | — | ||
| Q2 25 | -433.6% | 19.2% | ||
| Q1 25 | -1216.5% | — | ||
| Q4 24 | -13.4% | 8.7% | ||
| Q3 24 | -315.7% | — | ||
| Q2 24 | -302.4% | -15.4% | ||
| Q1 24 | -275.0% | — |
净利率ALECARGX
| Q4 25 | -597.5% | 35.5% | ||
| Q3 25 | -1063.4% | — | ||
| Q2 25 | -387.7% | 23.4% | ||
| Q1 25 | -1101.6% | — | ||
| Q4 24 | -3.8% | 64.1% | ||
| Q3 24 | -275.2% | — | ||
| Q2 24 | -256.4% | -3.6% | ||
| Q1 24 | -227.0% | — |
每股收益（稀释后）ALECARGX
| Q4 25 | $-0.34 | $13.25 | ||
| Q3 25 | $-0.34 | — | ||
| Q2 25 | $-0.30 | $6.32 | ||
| Q1 25 | $-0.41 | — | ||
| Q4 24 | $-0.02 | $13.33 | ||
| Q3 24 | $-0.43 | — | ||
| Q2 24 | $-0.40 | $-0.55 | ||
| Q1 24 | $-0.38 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $256.0M | $3.5B |
| 总债务越低越好 | $10.0M | — |
| 股东权益账面价值 | $30.6M | $7.3B |
| 总资产 | $293.2M | $8.7B |
| 负债/权益比越低杠杆越低 | 0.33× | — |
8季度趋势，按日历期对齐
现金及短期投资ALECARGX
| Q4 25 | $256.0M | $3.5B | ||
| Q3 25 | $291.1M | — | ||
| Q2 25 | $307.3M | $2.1B | ||
| Q1 25 | $354.6M | — | ||
| Q4 24 | $413.4M | $1.5B | ||
| Q3 24 | $457.2M | — | ||
| Q2 24 | $503.3M | $1.4B | ||
| Q1 24 | $562.1M | — |
总债务ALECARGX
| Q4 25 | $10.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $10.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $11.0M | ||
| Q1 24 | — | — |
股东权益ALECARGX
| Q4 25 | $30.6M | $7.3B | ||
| Q3 25 | $57.7M | — | ||
| Q2 25 | $71.2M | $6.1B | ||
| Q1 25 | $94.6M | — | ||
| Q4 24 | $126.8M | $5.5B | ||
| Q3 24 | $118.9M | — | ||
| Q2 24 | $150.6M | $4.3B | ||
| Q1 24 | $178.9M | — |
总资产ALECARGX
| Q4 25 | $293.2M | $8.7B | ||
| Q3 25 | $335.3M | — | ||
| Q2 25 | $356.4M | $7.2B | ||
| Q1 25 | $408.3M | — | ||
| Q4 24 | $468.3M | $6.2B | ||
| Q3 24 | $516.0M | — | ||
| Q2 24 | $570.7M | $4.8B | ||
| Q1 24 | $635.5M | — |
负债/权益比ALECARGX
| Q4 25 | 0.33× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.08× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-41.7M | $323.3M |
| 自由现金流经营现金流 - 资本支出 | — | $322.4M |
| 自由现金流率自由现金流/营收 | — | 13.0% |
| 资本支出强度资本支出/营收 | 0.0% | 0.0% |
| 现金转化率经营现金流/净利润 | — | 0.37× |
| 过去12个月自由现金流最近4个季度 | — | $594.5M |
8季度趋势，按日历期对齐
经营现金流ALECARGX
| Q4 25 | $-41.7M | $323.3M | ||
| Q3 25 | $-32.5M | — | ||
| Q2 25 | $-49.0M | $361.8M | ||
| Q1 25 | $-60.8M | — | ||
| Q4 24 | $-55.0M | $41.9M | ||
| Q3 24 | $-50.7M | — | ||
| Q2 24 | $-62.8M | $-124.7M | ||
| Q1 24 | $-61.3M | — |
自由现金流ALECARGX
| Q4 25 | — | $322.4M | ||
| Q3 25 | $-32.5M | — | ||
| Q2 25 | $-49.1M | $356.6M | ||
| Q1 25 | $-60.8M | — | ||
| Q4 24 | $-55.2M | $40.9M | ||
| Q3 24 | $-50.9M | — | ||
| Q2 24 | $-63.1M | $-125.5M | ||
| Q1 24 | $-61.9M | — |
自由现金流率ALECARGX
| Q4 25 | — | 13.0% | ||
| Q3 25 | -997.6% | — | ||
| Q2 25 | -623.0% | 20.1% | ||
| Q1 25 | -1655.0% | — | ||
| Q4 24 | -101.8% | 3.0% | ||
| Q3 24 | -332.1% | — | ||
| Q2 24 | -418.6% | -13.9% | ||
| Q1 24 | -389.3% | — |
资本支出强度ALECARGX
| Q4 25 | 0.0% | 0.0% | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 0.1% | 0.3% | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 0.3% | 0.1% | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | 2.2% | 0.1% | ||
| Q1 24 | 3.4% | — |
现金转化率ALECARGX
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.87× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
